A major US study published in JAMA Network Open found that Long Covid affects 16.3% of COVID-19 patients, roughly 1 in 6, more than double previous government estimates. The Apheresis Center in Larnaca, Cyprus, reports rising demand for its H.E.L.P. Apheresis treatment as US patients face a domestic coverage gap, with insurers classifying the procedure as experimental and denying coverage, leaving out-of-pocket costs of $15,000 to $30,000 for a full course. The clinic, founded by Markus Klotz after his own recovery, offers a structured protocol of five to eight sessions at €1,790 each, drawing patients who cite domestic scarcity and coverage denial as reasons for traveling abroad. H.E.L.P. Apheresis, a blood filtration technique originally developed for cholesterol disorders, is used to reduce microclots and inflammation in Long Covid and ME/CFS, with over 500,000 treatments documented and a low rate of severe complications.